75 results about "Prostate hyperplasia" patented technology

The invention relates to an AI image navigation method, device and equipment for prostatic hyperplasia minimally invasive surgery and a medium thereof. The method comprises the following steps: acquiring a prostate three-dimensional image and an intraoperative real-time image sequence, and fusing the three-dimensional image after preliminary filtering to obtain an optimized and enhanced image; based on the enhanced image and the preoperative three-dimensional image, a three-dimensional offset vector is obtained through a multi-modal registration algorithm combined with an anatomical structure reference, and optimized prostate three-dimensional attitude data is generated in combination with anatomical constraints; combining the attitude data and the three-dimensional image, determining boundary area distribution characteristics, calculating a risk assessment value, mapping a risk level, and generating a path correction instruction to obtain an instrument navigation path if the risk level exceeds a threshold value; and based on the navigation path, constructing a clinical recovery model in combination with the anatomical structure, generating postoperative recovery index simulation data, and performing adjustment and verification until preset requirements are met to obtain a final operation execution scheme. According to the method, precision and individuation of surgical navigation are achieved, and comprehensive technical support is provided for precise implementation of minimally invasive surgery.

The invention belongs to the technical field of medical robots and minimally invasive surgery, and provides a robot control system and method for blue laser vaporization surgery of prostatic hyperplasia. Mapping the nuclear magnetic image volume data to a deformation field under an ultrasonic acquisition coordinate system, and deforming the preoperative nuclear magnetic image to an intra-operative ultrasonic space by using the deformation field to complete image registration; fusing the registered image with a stereoscopic vision system; the spatial depth of the surface of the target tissue is obtained from the endoscopic image so as to supplement navigation information; according to the utility model, the prostate deformation and probe posture change adaptive capacity in an operation is improved, the real-time visual closed-loop regulation and control capacity is improved, and the characteristics of small light spots, shallow heat diffusion, excellent hemostasis and the like of blue laser are combined, so that the vaporization and hemostasis precision in a tiny blood vessel dense area is ensured, and the problems of large tissue trauma and the like are avoided.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia and a preparation method thereof. The composition is prepared from the following medicinal materials in parts by weight: 6 to 8 parts of radix aconiti lateralis preparata, 3 to 5 parts of cortex cinnamomi, 10 to 15 parts of fructus alpiniae oxyphyllae, 10 to 15 parts of fructus psoraleae, 5 to 10 parts of semen myristicae, 5 to 10 parts of ground beeltle, 8 to 12 parts of spina gleditsiae, 10 to 15 parts of radix angelicae sinensis, 8 to 12 parts of radix linderae, 15 to 20 parts of radix rehmanniae praeparata, 10 to 15 parts of fructus corni, 8 to 12 parts of rhizoma anemarrhenae, 15 to 20 parts of radix scrophulariae, 8 to 12 parts of rhizoma alismatis, 5 to 10 parts of radix stephaniae tetrandrae and 10 to 15 parts of radix cyathulae. The invention provides the self-prepared medicine composition for treating the prostatic hyperplasia, the diseases of patients with the prostatic hyperplasia are remarkably improved through the synergistic effect of all the medicines in the composition, and a new traditional Chinese medicine treatment thought is provided for clinical treatment of the BPH disease. According to the traditional Chinese medicine composition, medicine pairs are increased or decreased on the basis of referring to a traditional Chinese medicine classic treatment compound, the unique traditional Chinese medicine composition is finally formed, and all the medicine pairs in the formula cooperate with one another and are indispensable.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

A delivery device for positioning an implantable expander to a target location in a prostatic urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The invention relates to application of pulsatilla saponin D in preparation of a medicine for preventing or treating human prostatic hyperplasia. The invention shows that the pulsatilla saponin D has an inhibition effect on human prostate cell WPMY-1, HPRF and BPH-1 cell strains, and can cause cell apoptosis to a certain extent, so that the pulsatilla saponin D shows the effect of preventing or treating prostatic hyperplasia.

The invention discloses a traditional Chinese medicine composition for treating uroschesis caused by benign prostatic hyperplasia and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared by mixing leeches, radix semiaquilegiae, cortex phellodendri, rhizoma anemarrhenae, Chinese lobelia, polygonum cuspidatum, herba patriniae, dianthus superbus, cowherb seeds, lumbricus, pericarpium citri reticulatae viride and lindera aggregata and then decocting with water. According to the traditional Chinese medicine composition, treatment is carried out synergistically from the three aspects of rapid relieving of emergency symptoms, targeted treatment of pathologic roots and synchronous recovery of whole body metabolic balance, and the four-in-one comprehensive curative effect of diuretic, anti-male, anti-inflammatory and tissue repair is achieved; the traditional Chinese medicine composition is simple in preparation method, low in cost and wide in safety window, is applied to treatment of uroschesis caused by benign prostatic hyperplasia, and provides a family-friendly traditional Chinese medicine solution capable of replacing or being combined with existing chemical medicines for patients.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

The preparation method comprises the following steps: decocting urtica cannabina roots with water, carrying out macroporous resin, silica gel column chromatography and preparative HPLC (High Performance Liquid Chromatography) separation, and simultaneously preparing two kinds of high-purity urtica cannabina neoglycoside I (netleside I) and urtica cannabina neoglycoside II (netleside II) which have a remarkable prostatic hyperplasia resisting effect from urtica cannabina, thereby obtaining the urtica cannabina neoglycoside I (netleside I) and the urtica cannabina neoglycoside II (netleside II). The compound can be used for preparing anti-prostatic hyperplasia medicines; the method has the advantages of simplicity, rapidness, high purity, low production cost and the like.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

A catheter for deploying an implantable expander in a urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

Some embodiments of the invention advantageously leverage the expansion of the prostatic urethra using adjustable lumen tension rings (ALTRs) of desired sizes to control and improve flow throughout the range of the urethra. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the prostatic wall and is at least partially within the lumen and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the bladder or other locations within the urethra and / or elsewhere in the urethra. The expansion of the lumen can be pre-configured based on pre-operative metrology of the prostatic urethra to a customized and adjustable fit across the various zones within the urethra and based on the patient specific and evolving needs.

The application discloses an application of a prostate hyperplasia related marker in preparation of a product for detecting prostate hyperplasia, and the prostate hyperplasia related marker is at least one selected from MINP1, ACTBL and APOC4 proteins. In the technical scheme, MINP1, ACTBL and APOC4 are combined as a detection marker for prostate hyperplasia (BPH), so that the complementarity of the three in different stages of diseases can be fully exerted, and the comprehensive performance of the detection product is obviously improved. MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, and APOC4 can present significant expression changes in blood cells of early BPH patients, so that BPH disease screening can be accurately performed. When the three are applied in cooperation, early screening of BPH can be realized, and the activity and severity of the lesion can be evaluated, so that a detection system covering the whole process of disease occurrence and development is formed, the limitation of a single marker in the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

The present application relates to a new use of fluorocarbon phase transition microparticles as a therapeutic ablation agent for mechanically damaging or ablating diseased tissue. When fluorocarbon phase transition microparticles are in contact with diseased tissue, under the excitation of low-frequency focused ultrasound, gas-liquid phase transition (i.e. vaporization) and ultrasonic cavitation resonance of vaporized microbubbles occur, followed by controlled intensity cavitation and mechanical damage of local tissue, thereby producing an ablation therapeutic effect on diseased tissue. Vaporized fluorocarbon phase transition microbubbles become ideal exogenous cavitation nuclei, which can significantly reduce the cavitation threshold and induce enhanced inertial cavitation effects. This method has the characteristics of short treatment time, low required ultrasonic pressure and sound intensity, minimal damage to tissues outside the target area, easy operation, etc., improving the targeting and safety of treatment. Although this treatment method requires image guidance, it does not require very precise focusing, reducing the difficulty of operation, and has application prospects in multiple clinical treatment fields such as prostate hyperplasia and tumor immunotherapy.

A stent is disclosed that is configured to maintain patency of the prostatic urethra despite an enlarged prostate. The stent can include a handle that, in an undeflected position, is disposed outside of the flow path of the stent. When the handle is pulled, the handle can deflect to generally aligned with a central axis of the stent. A capture device is disclosed that includes a tapered tip to navigate a working channel of a delivery device and a hook that can capture the stent handle and be moved into a tube to retain the stent handle to facilitate maneuvering of the stent in and out of the working channel of the delivery device. A loading adapter with a tapered port is disclosed that can be disposed on the delivery device to distribute compressive forces applied by the port on the stent during loading into the working channel.

This invention discloses a biomarker, reagent kit, and system for diagnosing bladder injury secondary to benign prostatic hyperplasia (BPH), relating to the field of biomedical detection technology. The biomarker for diagnosing bladder injury secondary to BPH is characterized in that it includes urinary DAB2 protein. This invention achieves (1) clinical applicability: accurate quantitative assessment of the degree of injury. The most significant clinical value of urinary DAB2 protein lies in its ability to transform traditional subjective bladder injury assessment into an objective quantitative indicator. (2) convenient detection: non-invasive and rapid assessment using urine samples. As a urine detection biomarker, urinary DAB2 protein completely changes the traditional bladder injury assessment's reliance on invasive or expensive examinations such as cystoscopy and CT. (3) clinical decision support: the grading diagnostic value of urinary DAB2 protein is directly translated into clinical decision support capabilities, helping to avoid the clinical dilemma of "overtreatment" or "undertreatment."

The invention provides rape pollen and maca chewable tablets for resisting benign prostatic hyperplasia and a preparation method of the rape pollen and maca chewable tablets, and relates to the technical field of biological medicines. The rape pollen and maca chewable tablet takes a rape pollen extract and a maca extract as effective components, the rape pollen extract is obtained by performing high-voltage pulsed electric field treatment and ultrasonic extraction on rape pollen through a deep-eutectic solvent solution, and the maca extract is obtained by performing microbial anaerobic fermentation on maca powder. The rape pollen extract disclosed by the invention can inhibit 5alpha-reductase and reduce the generation of dihydrotestosterone; the maca extract can regulate an endocrine axis, improve immunity and microcirculation, relieve slight gastrointestinal irritation possibly brought by the rape pollen extract and improve the taking safety and compliance of the whole preparation; and the rape pollen extract and the maca extract have a synergistic effect, so that the prostatic hyperplasia can be remarkably inhibited. The chewable tablet can inhibit benign prostatic hyperplasia and can be used for preparing drugs for preventing and treating benign prostatic hyperplasia.

This invention discloses the application of inosine in the preparation of drugs that promote testosterone secretion, belonging to the field of biomedical technology. The effective active ingredient of the above-mentioned drugs is only inosine or its pharmaceutically acceptable salts. The dosage forms of the above-mentioned drugs are tablets, capsules, oral liquids, lozenges, granules, powders, pills, powders, ointments, elixirs, suspensions, powders, or injections. The routes of administration of the above-mentioned drugs are oral, transdermal, intramuscular, subcutaneous, or intravenous injection. Since inosine exists under physiological conditions and can be metabolized by intestinal microorganisms, reasonable supplementation of inosine is a safer and more effective method for restoring testosterone. Inosine helps maintain the homeostasis of the intestinal flora, and the experimental results of this invention further show that inosine can restore the damaged intestinal barrier, thus making it safer. Moreover, this invention does not directly supplement exogenous testosterone, therefore it is less likely to induce spermatogenesis disorders or promote prostatic hyperplasia.

The present invention relates to a pharmaceutical composition, a food composition and a feed composition for preventing, ameliorating or treating benign prostatic hyperplasia, each composition comprising an Alpiniae oxyphyllae Fructus extract, and a method for treating benign prostatic hyperplasia by using the pharmaceutical composition. The pharmaceutical composition, the food composition, and the feed composition exhibit the effect of inhibiting prostatic hypertrophy caused by male hormone imbalance, can reduce lower urinary tract symptoms caused by prostatic hypertrophy by inhibiting prostatic proliferation, and can be developed, through non-clinical and clinical studies, as pharmaceuticals that are effective in preventing and treating benign prostatic hyperplasia, health functional foods and health foods that are beneficial to prostate health, and the like.

The invention provides an astaxanthin composition containing an effective amount of astaxanthin. Furthermore, the invention provides an astaxanthin composition containing an effective amount of astaxanthin and xanthoceras sorbifolia bunge oil. Furthermore, the invention provides an astaxanthin composition containing an effective amount of astaxanthin, xanthoceras sorbifolia bunge oil, DHA algal oil and / or euphausia superba oil. Furthermore, the invention provides an astaxanthin composition containing an effective amount of astaxanthin, xanthoceras sorbifolia bunge oil, DHA algal oil and / or euphausia superba oil, and one or more vitamins. Furthermore, the invention provides application of the astaxanthin composition in the following fields: 1) relieving physical and visual fatigue; 2) improving fundus diseases and other eye symptoms, and promoting eye health; the astaxanthin / xanthoceras sorbifolia bunge oil composition has the advantages that the astaxanthin / xanthoceras sorbifolia bunge oil composition can be used for treating and improving prostatitis and benign prostatic hyperplasia, is beneficial to male health, can be used for promoting the basic metabolism level and realizing non-exercise fat reduction, and has a more remarkable action effect compared with a composition (agent) only containing an astaxanthin active component.

The present invention relates to the beneficial effect of Chebulinic acid (CA) and its enriched standardized fraction (CAEF) isolated / prepared from the fruits of Terminalia chebula for the management of Benign Prostatic Hyperplasia respectively. Further, it relates to a novel, convenient and economically viable method for the isolation of chebulinic acid (CA) and ellagic acid (EA) from the dried and powdered fruits of T. chebula without using any expensive and tedious chromatographic techniques such as HPLC, column chromatography, resins etc.

A catheter for deploying an implantable expander to a target location in a urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

The invention discloses a medicinal moxa composition for preventing and treating constipation and benign prostatic hyperplasia. The medicinal moxa composition comprises Chinese angelica, ligusticum wallichii, donkey-hide gelatin, cassia twig, white peony root, safflower, motherwort and moxa. Active volatile components contained in the medicinal moxa composition act on a plurality of key targets related to constipation and benign prostatic hyperplasia, participate in multi-channel regulation and control to synergistically play a treatment role, and directly regulate qi and blood circulation of related acupuncture points of the Ren channel through multiple ways of skin penetration, acupuncture point stimulation, infrared radiation and the like in moxibustion, so that the treatment effect is improved, and the treatment effect is improved. The pathological states of blood deficiency and downward flow of damp-heat are improved, and a new external treatment thought is provided for preventing and treating constipation and prostatic hyperplasia codiseases. A theoretical basis is provided for verifying related targets and pathways of the medicinal folium artemisiae argyi composition for preventing and treating the constipation and the prostatic hyperplasia co-disease, and a theoretical basis and a new practice direction are provided for healthy health-care research on the constipation and the prostatic hyperplasia co-disease.

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing a Hovenia dulcis extract as an active ingredient. Specifically, the Hovenia dulcis extract of the present invention was confirmed to inhibit the proliferation of hyperproliferative prostatic cells induced by dihydrotestosterone (DHT), which is a male hormone, and reduce prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

A delivery device for image-assisted delivery of an implantable expander in a urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

The invention provides application of TRMT61A as a target spot in preparation of a medicine for preventing or treating benign prostatic hyperplasia. The TRMT61A is specifically targeted through shRNA, pathogenic signals are blocked from the post-transcriptional level, accurate intervention on benign prostatic hyperplasia is achieved, dependence on androgen pathways is completely avoided, unavoidable sexual dysfunction and other serious side effects of traditional drugs are fundamentally avoided, and the life quality of patients is remarkably improved.

The invention provides a composition helpful for maintaining prostate health. The composition comprises the following raw materials in parts by weight: 3-5 parts of rape pollen, 0.1-0.5 part of lycopene powder, 0.1-0.2 part of a turmeric ethanol extract, 1-2 parts of a chicory extract, 1-2 parts of a dandelion extract and 1-2 parts of auxiliary materials. The invention also provides a preparation method and application of the composition helpful for maintaining prostate health. According to the invention, the rape pollen, the lycopene powder, the turmeric ethanol extract, the chicory extract and the dandelion extract have a synergistic effect to form a multi-target synergistic effect mechanism of reducing androgen metabolism, preventing inflammatory response and reducing oxidative damage, so that the traditional Chinese medicine composition can prevent and treat prostatic hyperplasia, also has an excellent effect on abacterial prostatitis, and is free of toxic and side effects. And the traditional Chinese medicine composition is safe, efficient and suitable for long-term administration. The invention belongs to the technical field of food and health care product processing.